TYU-30622-52094
3 vaccinations
4 coded responses
22 check-ins
4 free-text entries
1 call case
- Sex
- Female
- Age at first dose
- 36-40
- ZIP prefix
- 660 / KS
- Registered
- 2021-02-11
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-22
Dose 1 — Pfizer-BioNTech
-
2021-02-11
Registered in v-safe
- 2021-02-12
- 2021-02-19
-
2021-02-23
Dose 2 — Pfizer-BioNTech
-
2021-02-23
Survey response — day 0, dose 2MedDRA: Dizziness — Feeling: Fair · Fever · HeadacheFree text: LightheadedMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-24
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Chills, Headache, Joint pains, Muscle or body aches, Fatigue or tiredness, Diarrhea, Abdominal pain · Be unable to workAdult check-in
-
2021-02-25
Health check-in — days 1–6 daily, dose 2Feeling: Fair · Site: Pain · Fever · Headache, Joint pains, Muscle or body aches, Fatigue or tiredness · Be unable to do your normal daily activitiesAdult check-in
- 2021-02-28
- 2021-03-01
- 2021-03-02
- 2021-03-11
-
2021-03-18
Survey response — day 21, dose 2MedDRA: Headache, Vomiting — Feeling: FairFree text: Headache and vomiting.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-25
- 2021-04-01
- 2021-04-06
- 2021-05-25
- 2021-08-24
-
2022-02-23
Survey response — 12 months, dose 2MedDRA: Chills, Cough, Dyspnoea, Pyrexia, Respiratory tract congestion — Feeling: Good · Be unable to work or attend school, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Shortness of breath, cough, fever, chills, congestionMedDRA releases: 2024-11 · check-in free text available
-
2022-02-23
Report sent to call center — 12 months, dose 2Be unable to work or attend school · Be unable to do your normal daily activities · Get care from a doctor or other healthcare prTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-02-28
-
2022-03-10
Dose 3 — Pfizer-BioNTech
- 2022-03-10
-
2022-03-11
Health check-in — days 1–6 daily, dose 3Feeling: Fair · Site: Pain · Chills, Fatigue or tirednessAdult check-in
-
2022-03-12
Survey response — days 1–6 daily, dose 3MedDRA: Oropharyngeal pain — Feeling: Fair · Site: Pain, Redness · Fatigue or tirednessFree text: Sore throatMedDRA releases: 2024-11 · check-in free text available
-
2022-03-13
Health check-in — days 1–6 daily, dose 3Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2022-03-31
- 2022-04-16
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-22 | Pfizer-BioNTech | |
| 2 | 2021-02-23 | Pfizer-BioNTech | |
| 3 | 2022-03-10 | Pfizer-BioNTech | No |
Call center
1 call center case
1 unsuccessful
Free text
Release 4 — day 0, dose 2
Systemic reaction (other): Lightheaded
Release 5 — day 21, dose 2
Symptoms: Headache and vomiting.
Release 11 — 12 months, dose 2
Symptoms: Shortness of breath, cough, fever, chills, congestion
Release 11 — days 1–6 daily, dose 3
Systemic reaction (other): Sore throat
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| SD | Chills | · | · | ✓ |
| SD | Cough | · | · | ✓ |
| SD | Dyspnoea | · | · | ✓ |
| SD | Headache | ✓ | ✓ | ✓ |
| SD | Pyrexia | · | · | ✓ |
| SD | Respiratory tract congestion | · | · | ✓ |
| SD | Vomiting | ✓ | ✓ | ✓ |
| SRO | Dizziness | ✓ | ✓ | ✓ |
| SRO | Oropharyngeal pain | · | · | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release